Lower Rates of Resistance with Newer ART Regimens

Resistance mutations were detected most frequently with AZT/3TC and during periods of low-level viremia.

Although antiretroviral regimens containing AZT or lopinavir/ritonavir are falling out of favor in developed countries, they are still recommended by the WHO and used extensively in developing countries. These regimens confer a higher risk for the emergence of drug resistance than newer regimens, according to a recent analysis in the Swiss HIV Cohort Study.

Researchers analyzed data from 2263 patients who initiated combination antiretroviral therapy (ART) between 1999 and 2010 with the most commonly used regimens in the larger cohort:

AZT/3TC + efavirenz
Tenofovir + FTC (or 3TC) + efavirenz
AZT/3TC + lopinavir/r
Tenofovir + FTC (or 3TC) + lopinavir/r
Tenofovir + FTC (or 3TC) + boosted atazanavir

At each viral-load measurement, patients were classi…

Reviewing Author

Jonathan Z. Li, MD

Lower Rates of Resistance with Newer ART Regimens

Topics

Reviewing Author